Bristol-Myers Squibb sets up Centre for Molecular Synthesis with Princeton University
B-MS and Princeton scientists will collaborate on synthetic chemistry research
Global biopharmaceutical firm Bristol-Myers Squibb and the Department of Chemistry at Princeton University have announced a new research collaboration, which includes the establishment of a new Centre for Molecular Synthesis (BMS-CMS).
The agreement creates opportunities for scientists at Princeton University and Bristol-Myers Squibb to collaborate on synthetic chemistry research, taking advantage of their close proximity to foster an exchange of scientific ideas.
Financial terms of the agreement were not revealed.
'Bristol-Myers Squibb has a long history of engaging in external collaborations and partnerships of all shapes and sizes, always with an eye toward advancing science,' said Percy Carter, Head of Discovery Chemistry at Bristol-Myers Squibb.
'Similarly, the Department of Chemistry at Princeton University fosters an environment of collegiality, innovation and scientific rigour, and our scientists look forward to contributing to that through this research collaboration.'
The partners will investigate areas of mutual interest and benefit, using the expertise developed in the laboratories of the Princeton faculty to conduct leading edge science within the pharmaceutical industry.
Over the next five years, the Centre will also fund a selective group of research fellows each year. Each research fellow will be paired with a Bristol-Myers Squibb mentor who will provide scientific guidance and offer input from an industrial chemistry perspective. Fellows will also be able to interact with a variety of industrial researchers and learn firsthand how research is conducted in a pharmaceutical setting.